Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 9Small Cell Lung Carcinoma 6Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Neoplasms by Site 3Neoplasm Metastasis 3Endometrial Neoplasms 3Cholangiocarcinoma 3Neoplasms by Histologic Type 2Liver Neoplasms 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1

Interventions

Bevacizumab 3durvalumab 2atezolizumab 2Hepatectomy 2tremelimumab 1trastuzumab deruxtecan 1pembrolizumab 1Whole Genome Sequencing 1Standard of Care 1Specimen Handling 1Radionuclide Imaging 1Platinum 1Ipilimumab 1Immunotherapy 1Immunoglobulin G 1IMC-001 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Disulfides 1Diathermy 1Cisplatin 1Cell- and Tissue-Based Therapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liver Neoplasms × durvalumab × 30 days × Clear all
NCT03937830 2026-06-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡